[{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Virginia Contract Research Organization","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Overseas Pharma \/ Virginia Contract Research Organization","highestDevelopmentStatusID":"10","companyTruncated":"Overseas Pharma \/ Virginia Contract Research Organization"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Kangqi Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Overseas Pharma \/ Kangqi Medical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Kangqi Medical Technology"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Beijing CTSmed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ramelteon","moa":"Melatonin receptor","graph1":"Sleep","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Overseas Pharma \/ Beijing CTSmed","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Beijing CTSmed"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Beijing Capton Pharmaceutical Technology Development","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ Beijing Capton Pharmaceutical Technology Development","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Beijing Capton Pharmaceutical Technology Development"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"GX Pharma Technology","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Brivaracetam","moa":"Synaptic vesicle glycoprotein 2A","graph1":"Neurology","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ GX Pharma Technology","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ GX Pharma Technology"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Shanghai ShouYan Clinical Development Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd."},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Shanghai ShouYan Clinical Development Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Shanghai ShouYan Clinical Development Co.,Ltd."},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Health Start Pharmaceutical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ Health Start Pharmaceutical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Health Start Pharmaceutical Technology"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Kangqi Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Felodipine","moa":"Voltage-gated L-type calcium channel | Mineralocorticoid receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Overseas Pharma \/ Kangqi Medical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Kangqi Medical Technology"}]

Find Clinical Drug Pipeline Developments & Deals by Overseas Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Ramelteon is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Sleep Initiation and Maintenance Disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 24, 2025

                          Lead Product(s) : Ramelteon

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase I

                          Sponsor : Beijing CTSmed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pirfenidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Pirfenidone

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pirfenidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Pirfenidone

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pirfenidone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 26, 2024

                          Lead Product(s) : Pirfenidone

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Shanghai ShouYan Clinical Development Co.,Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lacosamide is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          March 28, 2023

                          Lead Product(s) : Lacosamide

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Beijing Capton Pharmaceutical Technology Development

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 15, 2023

                          Lead Product(s) : Ibuprofen

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Kangqi Medical Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Amlodipine Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 29, 2022

                          Lead Product(s) : Amlodipine Besylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Health Start Pharmaceutical Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Brivaracetam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Seizures.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          November 18, 2022

                          Lead Product(s) : Brivaracetam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : GX Pharma Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Felodipine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 14, 2022

                          Lead Product(s) : Felodipine

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Kangqi Medical Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Ibuprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Chronic Pain.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 15, 2022

                          Lead Product(s) : Ibuprofen

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank